Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   Google Scholar
• Tarantino P, Prat A, Cortes J, et al. Third-line treatment of HER2-positive advanced breast cancer: from no standard to a pandora’s box. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188487.
   Google Scholar
• Zhu Y, Zhu X, Wei X, et al. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188549.
   Google Scholar
• Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40(6):770–780.
   Google Scholar
• Jhaveri K, Esteva FJ. Pertuzumab in the treatment of HER2+ breast cancer. J Natl Compr Canc Netw. 2014;12(4):591–598.
   Google Scholar
• D-Y O, Bang Y-J. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.
   Google Scholar
• von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205.
   Google Scholar
• Prescribing information KADCYLA. February 2013.2021 Feb 20. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf
   Google Scholar
• ENHERTU. Prescribing information. December 2019. 2021 Feb 20. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf
   Google Scholar
• Vedotin D. Prescribing information. 2021 Feb 20. 2021 Jun 2021. Available from: https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTg2ODc3Jml0ZW1JZD1mZjgwODA4MTdjODMxMmM0MDE3YzliYmZjOGRlMDM2MA==.
   Google Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39.
   Google Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356.
   Google Scholar
• Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873–1881.
   Google Scholar
• Uppsala Monitoring Centre (UMC). Analytical methods developed by the UMC research team are integrated in VigiLyze. Feb 15, 2021. Available from 2021 Feb 15: https://who-umc.org/vigibase/.
   Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372(n160):36. DOI:10.1136/bmj.n160
   Google Scholar
• Lopes-Júnior LC, Bomfim E, Olson K, et al. Effectiveness of hospital clowns for symptom management in paediatrics: systematic review of randomised and non-randomised controlled trials. BMJ. 2020;371:m4290.
   Google Scholar
• Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105–114.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928.
   Google Scholar
• Brockhaus AC, Bender R, Skipka G. The Peto odds ratio viewed as a new effect measure. Stat Med. 2014;33(28):4861–4874.
   Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.
   Google Scholar
• Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in -mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241–251.
   Google Scholar
• Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430.
   Google Scholar
• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–789.
   Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701.
   Google Scholar
• Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135.
   Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653.
   Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295.
   Google Scholar
• Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733–5740.
   Google Scholar
• Krop IE, Kim S-B, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754.
   Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–126.
   Google Scholar
• Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913–925.
   Google Scholar
• Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173–1182.
   Google Scholar
• Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154.
   Google Scholar
• Saura Manich C, Modi S, Krop I, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01) [Conference Abstract]. Annals of Oncology, Lugano, Switzerland. 2021;32:S485–S486.
   Google Scholar
• Saura Manich C, O’Shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer [Journal: conference Abstract]. Annals of oncology, Lugano, Switzerland. 2021;32:S1288.
   Google Scholar
• Bellon JR, Tayob N, Burstein HJ, et al. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer [Journal: conference Abstract]. Int J Radiat Oncol Biol Phys. 2021;111(3):S34‐.
   Google Scholar
• van Cutsem E, Di Bartolomeo M, Smyth E, et al. LBA55 primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen [Conference Abstract]. Annals of Oncology, Lugano, Switzerland. 2021;32:S1332.
   Google Scholar
• Wuerstlein R, Ellis P, Montemurro F, et al. Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): final results from KAMILLA Cohorts 1 (global) and 2 (Asia) [Conference Abstract]. J Clin Oncol. 2021;39(15 SUPPL):1039.
   Google Scholar
• Waks AG, Keenan T, Li T, et al. A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC) [Conference Abstract]. J Clin Oncol. 2020;38(15):1046.
   Google Scholar
• A study of the efficacy and safety of trastuzumab emtansine (Trastuzumab-MCC-DM1) vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease. ClinicalTrials.gov Identifier: NCT00679341. Updated January 9, 2014. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT00679341?term=NCT+00679341&draw=2&rank=1.
   Google Scholar
• a study to evaluate the efficacy and safety of trastuzumab emtansine versus the combination of trastuzumab plus docetaxel in patients with her2-positive breast cancer. clinicaltrials.gov identifier: NCT02144012. Updated 2017 Mar 7. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT02144012?term=NCT+02144012&draw=1&rank=1.
   Google Scholar
• A study of trastuzumab emtansine versus capecitabine + lapatinib in participants with HER2-positive locally advanced or metastatic breast cancer (EMILIA).clinicaltrials.gov identifier: NCT00829166. Updated October 31, 2016. Accessed December 1, 2021.
   Google Scholar
• A study of trastuzumab emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus trastuzumab [Herceptin] plus a taxane in participants with metastatic breast cancer (MARIANNE). clinicaltrials.gov Identifier: NCT01120184. Updated November 7, 2017. Accessed December 1, 2021.
   Google Scholar
• A study of trastuzumab emtansine (Kadcyla) plus pertuzumab (Perjeta) following anthracyclines in comparison with trastuzumab (Herceptin) plus pertuzumab and a taxane following anthracyclines as adjuvant therapy in participants with operable HER2-positive primary breast cancer. ClinicalTrials.gov Identifier: NCT01966471. Updated 2021 Sept 30. 2021 Dec 1. Available from: https://wwwclinicaltrials.gov/ct2/show/results/NCT01966471?term=NCT+01966471&draw=1&rank=1.
   Google Scholar
• A study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-Positive, locally advanced or metastatic breast cancer. ClinicalTrials.gov Identifier: NCT00951665. Updated June 24, 2016. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT00951665?term=NCT+00951665&draw=2&rank=1.
   Google Scholar
• A study of trastuzumab emtansine (T-DM1) in combination with docetaxel, and potentially pertuzumab, in participants with advanced breast cancer. clinicaltrials.gov identifier: NCT00934856. Updated April 6, 2017. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT00934856?term=NCT+00934856&draw=2&rank=1.
   Google Scholar
• A study of trastuzumab-Mcc-DM1 administered intravenously to patients with HER2-positive metastatic breast cancer. clinicaltrials.gov identifier: NCT00679211. Updated 2017 Mar 31. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT00679211?term=NCT+00679211&draw=2&rank=1.
   Google Scholar
• BYL719 + T-DM1 in HER2(+) metastatic breast cancer pts who progress on prior trastuzumab & taxane tx. clinicaltrials.gov identifier: NCT02038010. Updated June 29, 2020. Accessed December 1, 2021. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT02038010?term=NCT+02038010&draw=1&rank=1.
   Google Scholar
• A study of trastuzumab emtansine (Trastuzumab-MCC-DM1, T-DM1) in combination with pertuzumab administered to patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who have previously received trastuzumab. ClinicalTrials.gov Identifier: NCT00875979. Updated December 24, 2013. Dec 1, 2021. Available from 2021 Dec 1: https://www.clinicaltrials.gov/ct2/show/results/NCT00875979?term=NCT+00875979&draw=1&rank=1.
   Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621.
   Google Scholar
• HERCEPTIN. Prescribing information. Sept 1998. 2021 Feb 20. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/103792Orig1s5349ltr.pdf
   Google Scholar
• Shitara K, Baba E, Fujitani K, et al. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer. 2021;24(4):780–789.
   Google Scholar
• Diéras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014;32(25):2750–2757.
   Google Scholar
• Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23–39.
   Google Scholar
• Yin O, Iwata H, Lin -C-C, et al. Exposure-response relationships in patients With HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan. Clin Pharmacol Ther. 2021;110(4):986–996.
   Google Scholar
• Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.
   Google Scholar
• Powell CA, Camidge DR, Modi S, et al. Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies [Conference Abstract]. Annals of Oncology. 2020;31:S357–S358.
   Google Scholar
• Kish JK, Mehta, S, Kwong, J, et al. Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan. Journal of Clinical Oncology. 2022;40(16_suppl): 1036–1036. DOI:10.1200/JCO.2022.40.16_suppl.1036 .
   Google Scholar
• Kinniry P SID-ildCTACCMWsAahwctchd-s-i-m.
   Google Scholar
• Kumagai K, Aida T, Tsuchiya Y, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–4645.
   Google Scholar
• Spira A, Lisberg A, Sands J, et al. OA03.03 datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study [Conference Abstract]. J Thorac Oncol. 2021;16(3):S106–S107.
   Google Scholar
• Xu Z, Guo D, Jiang Z, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.
   Google Scholar
• Frenkel S, Solomon A, Pe’er J. A novel type of corneal epitheliopathy from a new class of antibody-drug conjugate anticancer treatments [Conference Abstract]. Invest Ophthalmol Visual Sci. 2020;61(7):3633.
   Google Scholar
• Bargh JD, Isidro-Llobet A, Parker JS, et al. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48(16):4361–4374.
   Google Scholar
• Nakada T, Masuda T, Naito H, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016;26(6):1542–1545.
   Google Scholar
• Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–185.
   Google Scholar
• Conilh L, Fournet G, Fourmaux E, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021;14(3):247.
   Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22(20):5097–5108.
   Google Scholar
• Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404.
   Google Scholar
• ENHERTU®: Daiichi Sankyo, Inc. and AstraZeneca; 2021 [updated 2021]; ENHERTU®. [cited 2021 Feb 20]. Available from: https://www.enhertu.com/en/.
   Google Scholar
• KADCYLA®: Genentech USA, Inc.; 2022 [ updated 2022]. [cited 2021 Feb 20]. Available from: https://www.kadcyla.com.
   Google Scholar
• Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88(1):74–79.
   Google Scholar
• Yin O, Xiong Y, Endo S, et al. population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors. Clin Pharmacol Ther. 2021;109(5):1314–1325.
   Google Scholar
• Abuhelwa Z, Alloghbi A, Alqahtani A, et al. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82(9):979–987.
   Google Scholar